Effects of glutathione depletion on the cytotoxicity of agents toward a human colonic tumour cell line. by Jordan, J. et al.
Br. J. Cancer (1987), 55, 627-63 1
The Macmillan Press Ltd.,
Effects of glutathione depletion on the cytotoxicity of agents toward a
human colonic tumour cell line
J. Jordan, M. d'Arcy Doherty & G.M. Cohen
Toxicology Unit, Department ofPharmacology, The School ofPharmacy, University ofLondon, 29/39 Brunswick Square,
London WCIN lAX, UK.
Summary Levels of glutathione (GSH) in tumour tissue may be important in determining the clinical
response to certain anticancer agents. Recent reports have suggested that D,L-buthionine-S,R-sulphoximine
(BSO), a specific inhibitor of GSH synthesis, may be used to deplete tumour cell GSH and thus increase the
therapeutic ratio of these agents. We have previously shown that 1-naphthol is a potential antitumour agent,
and that its possible metabolite 1,4-naphthoquinone is thiol reactive and capable of redox cycling. It was
therefore of interest to investigate the effect of pretreatment with BSO, on the toxicity of these agents, to
tumour cells. For comparison we included three other cytotoxic agents, melphalan, helenalin and menadione,
the toxicities of which are reported to be modulated by intracellular GSH. Depletion of GSH using BSO did
not effect the toxicity of 1-naphthol, or 1,4-NQ but did produce slight potentiation of the cytotoxicities of
menadione, helanalin and melphalan. The lack of effect of BSO on 1-naphthol and 1,4-NQ is not easily
explained but if one also considers the modest potentiation of cytotoxicity achieved with the other agents
studied, the potential use of BSO in combined chemotherapy is at best rather modest.
Based on our findings that l-naphthol is selectively toxic to
short term organ cultures of human colonic tumour tissue
compared to normal colonic tissue from the same patients,
we suggested the potential use of l-naphthol or related
compounds in cancer chemotherapy (Cohen et al., 1983;
Wilson et al., 1985). Recently we have also shown an
antitumour activity of l-naphthol against Ehrlich ascites
tumour cells (Jones et al., 1987) and it therefore is of interest
to elucidate its mechanism of toxicity and formation of
possible reactive metabolites. l-Naphthol may be metabolised
by a microsomal mixed function oxidase to cytotoxic
naphthoquinones, primarily 1,4-naphthoquinone (d'Arcy
Doherty et al., 1984a,b, 1985). The toxicity of both 1-
naphthol and its possible metabolites 1,2-naphthoquinone
and 1,4-naphthoquinone, to isolated hepatocytes, is prececed
by a rapid depletion of intracellular glutathione (GSH)
(d'Arcy Doherty et al., 1984b).
GSH is the major nonprotein thiol in the cell and plays a
critical role in cellular defences against oxidative stress, free
radicals and alkylating agents (Meister & Anderson, 1979).
One of the problems associated with chemotherapy is the
wide range of sensitivities to treatment with any or one
agent, which is thought to be, in part, due to the differences
in sulphydryl levels in tumours. Several recent reports, have
therefore considered the potential of modulating intracellular
GSH levels in order to increase the chemotherapeutic
efficacy of certain antitumour agents, whose toxicity is
modulated by GSH (Akman et al., 1985; Arrick et al., 1983;
Capranico et al., 1986; Hamilton et al., 1985; Russo et al.,
1986; Suzukake et al., 1982, 1983).
The cytotoxic and antitumour effects of certain quinones
e.g. adriamycin and menadione, are thought to be related to
oxidative stress which arises through the capacity of those
compounds to redox cycle (Kappus & Sies, 1981; Thor et al.,
1982). Flavoenzymes catalyze a one electron reduction of
naphthoquinones to form semiquinone radicals which can
readily autoxidise in the presence of molecular oxygen (02)
forming large amounts of the superoxide anion radical
(O°-), which may then in turn spontaneously, or in a
reaction catalysed by superoxide dismutase, dismutate to
produce hydrogen peroxide (H202) which in turn may
undergo a metal catalysed reaction forming hydroxyl radical
(OH'), an extremely powerful oxidant (Bachur et al., 1978;
Thor et al., 1982; Wendel et al., 1981; Powis et al., 1981).
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This may lead to conditions of oxidative stress, lipid peroxi-
dation, damage to DNA and other vital cellular constituents
(Smith et al., 1985). GSH may protect against naphtho-
quinone mediated oxidative stress in several ways, including
direct reaction with the parent naphthoquinone or its semi-
quinone radicals, or by removing with glutathione peroxi-
dase either H202 formed or hydroperoxides produced as a
result of lipid peroxidation (Nickerson et al., 1963; Wendel
et al., 1981). It seems reasonable therefore, to suggest that
GSH may play a role in the protection of tumour cells
against 1-naphthol or its possible metabolite, 1,4-naphtho-
quinone. In this study, intracellular GSH was depleted in
LoVo cells, a human colonic adenocarcinoma cell line
(Drewinko et al., 1976), using DL-buthionine-S-R sulphoxi-
mine (BSO), a specific inhibitor of y-glutamyl cysteine
synthetase, the rate limiting enzyme in GSH synthesis
(Griffith & Meister, 1979), and the effect on the toxicity of
l-naphthol and its possible metabolite 1,4-naphthoquinone
were studied. For comparison, we included menadione (2-
methyl-1,4-naphthoquinone) and two alkylating agents,
melphalan and helenalin. The chemosensitivity of melphalan
and helenalin has previously been shown to be increased in
the presence of BSO. Tumour cell lines resistant to the
alkylating agent melphalan were found to have elevated
GSH and GSH S-transferase levels and sensitivity was
restored using BSO, to deplete GSH, in such cell lines
(Green et al., 1984; Hamilton et al., 1985). BSO has also
been shown to augment the lysis of tumour cells by
helenalin, therefore this agent was included as a positive
control (Arrick et al., 1983). Menadione, a derivative of
vitamin K has been extensively studied, with regard to
quinone toxicity and its reactions with GSH (Thor et al.,
1982) and is currently undergoing clinical trial with the
antimetabolite 5-fluorouracil (Chlebowski et al., 1983).
Depletion of GSH using BSO did not effect the toxicity of
1-naphthol or 1,4-naphthoquinone, as assessed by two end-
points of toxicity. However moderate potentiation was
observed with helenalin, melphalan and menadione. As the
effect of BSO on the cytotoxicity of all these agents was not
dramatic - the potential use of BSO in combined therapy in
the clinic may be limited.
Materials and methods
Cell Culture
LoVo human carcinoma cells (Drewinko et al., 1976)
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100 supplied by Dr Bridget Hill, ICRF London, were grown in
monolayer culture in Hams F-12 medium supplemented with
10% foetal calf serum (Flow Labs), I mM L-glutamine,
penicillin 100uml-1 and streptomycin 100/pgml-l (Gibco).
The cells were maintained at 37°C in a humidified atmos-
phere of 5% CO2 and routinely subcultured each week. Cells
in exponential growth phase were used in all experiments.
Drug exposure and cytotoxicity
For assay of protein synthesis inhibition, 200 p1 aliquots of a
cell suspension of density 5 x 104 cellsml- 1, were seeded into
96 wells of a flat-bottomed microtitre plate. The ability of
agents to inhibit 3H-leucine incorporation into protein was
carried out as previously described (Wilson et al., 1985).
For cell growth determinations, 1.5ml of a
1.4 x 104cells ml-1 suspension of cells were seeded into 3 cm
diameter petriplates. After incubation overnight at 37°C, 5%
C02, the medium was removed and replaced with complete
drug-free medium or medium containing 0.2mM BSO and
again incubated overnight (18 h). Cells were then exposed for
5h to the cytotoxic agents in fresh medium in the presence
or absence of 0.2 mM BSO, as before. After 5 h the medium
was then removed by aspiration, replaced with fresh medium
and incubated for a further 48 h at 37°C, 5% C02, and the
cell number estimated by counting an aliquot of trypsinised
cells with a Coulter Counter. All experiments were repeated
3-6 times and standard errors calculated.
GSH determination
In cultured cells Monolayer cultures in 3 cm dishes were
washed twice with 0.9% saline and the GSH extracted with
6.5% TCA at 4°C for 10min. GSH was assayed by the
method of Hissin and Hilf (1976) using o-phthalaldehyde (o-
PT) and results expressed as nmol GSH 10-6 cells.
Following chemical reactions of test agents with GSH Vari-
ous concentrations of the chemicals were incubated at
37°C in HEPES (10mM) (pH 7.5) with 100puM GSH and the
GSH remaining determined using o-P as before.
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Figure 1 Time course of GSH depletion in LoVo cells, fol-
lowing exposure to BSO. Results are expressed as a percentage
ofGSH present in untreated cells. (0 0) 0.05 mM; (A- A)
0.1 mm and (O----Q) 0.2mM BSO.
was obtained with viabilities of 98% +2.1 and 95.4+8.9% as
assessed by protein synthesis inhibition and cell numbers,
respectively. A concentration of BSO (0.2mM) was therefore
chosen for overnight incubation (18h) to deplete GSH.
Effect ofGSH modulation on the cytotoxicity ofthe chemicals
Results to LoVo cells
Effect ofBSO on tumour cell GSH
BSO (0.05-0.2mM) caused a time dependent depletion of
GSH (Figure 1) from a starting level of 6.6+0.7 nmol
GSH 10-6 cells present in control cells. After 24h exposure
to BSO (0.2mM), a maximum depletion to 12% of control
After exposure of LoVo cells to 1-naphthol for 5 h, protein
synthesis inhibition was a more sensitive indicator of cyto-
toxicity than cell numbers, 48h after exposure (Table I). The
opposite effect was observed with melphalan, when the IC50
values obtained using cell numbers was one fifth that
determined by protein synthesis inhibition (Table I). For all
Table I Effect of BSO on the cytotoxicity of the chemicals to LoVo cells
IC50PM IC50PM
(using 3H-leucine) (using Cell Number)
Chemical -BSO +BSO DMFP +BSO -BSO DMFP
1-Naphthol 543+34 540+41 1 950+ 134 960+ 154 1
l,4-NQ 13+1.5 13+1.5 1 25.5+6.2 24.5+6.3 1
Menadione 30.4+3.3 23.8+4.8 1.27b 24.6+6.2 19.5+5.6 1.8b
Helenalin 3.80+0.2 1.53+0.7 2.48b 2.6+0.9 1.07+0.6 2.4b
Melphalanc 57.8+5.6 43+11 1.38b 12.7+3.8 6.7+1.7 1.9
'DMF=Dose modification factor; bSignificant difference (P<0.05) between 'C50
values +BSO, using a paired t-test; cSignificant difference (P<0.05) between 'C50
values determined by the two criteria of assessing cytotoxicity, using a paired t-test.
Each experiment was repeated at least three times and a minimum of four wells per
concentration was used in every experiment.GLUTATHIONE DEPLETION AND CYTOTOXICITY 629
other agents used in this study i.e. menadione, helenalin, and
1,4-NQ, no significant difference in the IC50 values, as
assessed by either criteria were observed (Table I).
Depletion of GSH using BSO, did not effect the cyto-
toxicity of l-naphthol, or 1,4-naphthoquinone as assessed by
either method of toxicity, whereas the cytotoxicities as
assessed by inhibition of protein synthesis, of menadione,
helenalin and melphalan were significantly potentiated due to
pretreatment and incubation with BSO (Table I). BSO
treatment also potentiated the cytotoxicity of menadione and
helenalin, as assessed by cell numbers. A small but not
significant effect was observed with melphalan. The
maximum modification of an IC50 value in the presence of
BSO was a 2.5 fold decrease in the helenalin IC50 value
(Figure 2), all other effects were less than 2 fold.
a 3H-Leucine b Cell number
-5
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Figure 2 Effect of BSO on the toxicity of helenalin to LoVo
cells. (a) Protein synthesis was assessed by incorporation of 3H-
leucine and (b) cells numbers were determined 48h after drug
exposure. *Significant at P<0.05 paired t-test.
Effects ofchemicals on tumour cell GSH
LoVo cells were incubated with equitoxic concentrations (as
assessed by protein synthesis inhibition after 5h exposure)
and the GSH levels determined over a 2h exposure (Figure
3). Within 30min, 1,4-NQ caused over 95% depletion of
GSH in LoVo cells and this level was maintained over the
2h exposure. Menadione also caused an extensive but
insignificant, depletion due to the large variation in the
response. Melphalan and 1-naphthol did not deplete GSH,
however helenalin actually caused a small but not significant
increase in GSH above control value at 30min which
returned to normal at 60 and 120min (results not shown).
Reactivity ofchemicals with GSH in solution
The chemicals were incubated with GSH in buffered solution
(Figure 4). l-Naphthol (100yuM- mM) did not react with
GSH in solution whereas 1,4-NQ was highly reactive. After
15min incubation with 1004uM 1,4-NQ, less than 10% of the
GSH present at the start of the incubation (100yM)
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Figure 3 Effect of equitoxic concentrations of cytotoxic
chemicals on tumour cell GSH. The GSH levels after 30min
exposure are shown and the results are expressed as percentage
GSH present in untreated cells. The concentrations of l-
naphthol, 1,4-NQ, menadione, melphalan and helenalin were
250, 10, 20, 20 and 1 1iM respectively. *Significant P<0.05
unpaired t-test.
remained (Figure 4). Overall reactivity of the chemicals with
GSH in solution followed the order 1,4-NQ>menad-
ione>melphalan
- helenalin>>1-naphthol.
Discussion
Our results demonstrate that GSH depletion, using BSO to
inhibit GSH synthesis, may affect the cytotoxicity of selected
agents to LoVo cells growing in vitro (Table I). Cytotoxicity
was assessed by inhibition of both protein synthesis and cell
numbers. In a previous study with LoVo cells, little
difference was observed in the toxicity of 1-naphthol or
1,4-NQ, when assessed either by inhibition of protein syn-
thesis or by a clonogenic assay (Wilson et al., 1985). The
possibility that BSO or the drug treatments altered the
uptake of [3H]-leucine or its pool sizes cannot be excluded.
However in a similar study with human lung tumour cells,
BSO did not affect the uptake of [14C]-leucine (Brodie &
Reed, 1985). The cytotoxicity of l-naphthol assessed by
protein synthesis inhibition or cell number determination
after 24h, was not affected by BSO, indicating that GSH
may not be involved in protecting LoVo cells from the
toxicity of l-naphthol. In addition, BSO did not affect the
cytotoxicity of 1,4-NQ, a possible metabolite of l-naphthol.
Based on these results, the possible involvement of 1,4-NQ in
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Figure 4 Chemical interaction of agents with GSH in solution. Results are expressed as percentage GSH remaining after 15min
incubation at 37°C. *Significant at P<0.05 unpaired t-test.
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Table II Effects of glutathione depletion on the cytotoxicity of antitumour agents
Measurement DMFP
Treatment Cell line oftoxicity Effect (ifgiven) Ref.
Helenalin P815 51 Cr potentiation 4.7 Arrick et al. (1983)
Jatrophone P815 51 Cr potentiation 21.3
Adriamycin P815 51 Cr none Armck et al. (1983)
ADR resistant clonogenic sensitisation Hamilton et al. (1985)
V79 clonogenic potentiation 4-10.5 Russo et al. (1986)
A549 clonogenic none Russo et al. (1986)
Daunorubicin P388 cell number none Romine & Kessel
P388/ADR none (1986)
resistant
Bisthiosemi- P388 cell number potentiation 3.4 Romine & Kessel
carbozone P388/ADR cell number potentiation/ 1.4 (1986)
B2844 resistant sensitisation
H202
-preformed P815 51 Cr none Arrick et al. (1982)
endotheial 51 Cr potentiation Tsan et al. (1985)
generated P815 51 Cr potentiation 3.5 Arrick et al. (1982)
endothelial 51 Cr potentiation Tsan et al. (1982)
Melphalan A1847 LPAM clonogenic sensitisation 3.5-10 Green et al. (1984)
(L-PAM) resistant
L1210 clonogenic sensitisation Somfai-Relle et al.
LPam resistant (1984)
BCNUb P815 51 Cr none 0.99 Arrick et al. (1982)
Vinblastine 51 Cr none 1.17
Cytosine 51 Cr none 0.74
Arabinoside (Arac) 0.71
Maytansine 51 Cr none 0.91
Irradiation lymphoid trypan blue potentiation Dethmers &
(DTNB)C exclusion potentiation Meister (1981)
5-Fluorouracil none
Vincristine none
Neocarzino- V79 clonogenic protection DeGraff et al. (1985)
statin CCL-210 clonogenic none Russo et al. (1986)
(normal)
aDose modifying factor; b1,3-bis[2-chloroethyl]-l-nitrosourea; C5,5-dithiobis(2-nitrobenzoic acid).
the toxicity of l-naphthol cannot be excluded. The lack of
effect of BSO on the toxicity of both 1-naphthol and 1,4-NQ
was rather surprising, as with isolated hepatocytes both these
compounds caused a depletion of intracellular GSH prior to
cell death (d'Arcy Doherty et al., 1984b). However with
LoVo cells, 1,4-NQ but not l-naphthol, caused a depletion
in GSH (Figure 2). This may be due to differences in the
ability of these different cell types to activate these
compounds or to deal with the accompanying oxidative
stress.
It was of interest that under the same conditions, BSO
caused a small but significant potentiation of menadione
cytotoxicity but had no effect on the structurally related 1,4-
NQ (Table I). One possible explanation for this difference is
that the two quinones may exert their toxicity by different
mechanisms due to the higher chemical reactivity of 1,4-NQ
(Figure 4).
The cytotoxicities of the two alkylating agents in the
study, helenalin and melphalan, were potentiated in the
presence of BSO (Table I) in agreement with other studies
(Arrick et al., 1983; Green et al., 1984; Hamilton et al., 1985;
Suzukake et al., 1982). Of the four chemicals used in this
study the greatest potentiation of cytotoxicity in the presence
of BSO was exhibited by helenalin (Table I and Figure 2).
GSH may protect against helenalin cytotoxicity by conju-
gation, prior to alkylation of target molecules, prevent cross
linking or restore critical sulphydryl groups (Hall et al.,
1977, 1978). It is of interest to note that in the presence of
helenalin (1-10 MM), LoVo cell GSH Was not depleted,
suggesting that modulation of GSH may be of importance in
determining the toxicity of agents that do not deplete GSH.
Recently a number of studies have investigated the
possible relationship between resistance to melphalan (L-
PAM mustard), a bifunctional alkylating agent and thiol
status of the cells (Suzukake et al., 1983). In this study, a
modest potentiation of melphalan toxicity, to LoVo cells was
observed in the presence of BSO suggesting a protective role
for GSH against the cytotoxic action of melphalan, probably
via conjugation reactions. This potentiation of melphalan
toxicity was less than that observed by others (Table II) and
may be due to a number of possibilities such as the different
measures of cytotoxicity used or to lower intracellular levels
of GSH in the LoVo cells.
In vitro studies with tumour cells in this laboratory have
investigated the involvement of GSH in protection against a
range of cytotoxic agents. We observed that the cyto-
toxicities of menadione, helenalin and melphalan were
potentiated due to GSH depletion by BSO, however the
effects of BSO were relatively modest (Table I). It is of
particular interest to compare these results with other studies
in the literature to assess the potential use of BSO in
chemosensitising tumour cells (Table II). BSO has been
reported to increase drug toxicity, sensitise drug resistant cell
lines and also reduce drug toxicity. The majority of effects
are clearly very modest and some results actually conflict,
possibly due to different effects in different cell lines. Under
in vitro conditions, it is possible to choose a concentrationGLUTATHIONE DEPLETION AND CYTOTOXICITY 631
and time period of BSO exposure which would cause
optimal GSH depletion, prior to incubation with the
cytotoxic chemicals. If, under such optimum conditions, only
a slight potentiation of toxicity is observed, it is difficult to
envisage any great potentiation of toxicity to the tumour
tissue occurring in vivo, especially as it will be necessary to
consider other important factors such as the pharmaco-
kinetics of BSO and the antitumour agent. Furthermore
GSH depletion in vivo due to administration of BSO will not
be confined to tumour tissue therefore potentiation of
toxicity to normal tissue may be a limiting factor as was
recently observed with the enhanced nephrotoxicity of rats
treated with BSO (Kramer et al., 1985).
Our results and those of others suggest that great caution
should be exercised in the potential use of BSO in the
chemosensitisation of tumours in man.
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